Novo Nordisk Faces Dual Setbacks as Growth Slows and Acquisition Battle Intensifies

Danish pharmaceutical leader Novo Nordisk delivered a double blow to investors this Wednesday, presenting both another reduction in annual targets and an escalating multi-billion dollar contest for U.S. biotech firm Metsera. With the remarkable success of its flagship products Ozempic and Wegovy showing signs of stagnation, the company’s recently appointed chief executive is adopting a bold strategic shift. Market participants are now questioning whether this assertive new direction can successfully reverse the current trend.

In a move highlighting its revised strategic priorities, Novo Nordisk has significantly increased its unsolicited bid to acquire Metsera, now valuing the U.S. biotech specialist at up to $10 billion. This action directly challenges Read more...